Opinion
MDL NO. 6:11-md-2299
10-14-2016
IN RE: ACTOS (PIOGLITAZONE) PRODUCTS LIABILITY LITIGATION THIS DOCUMENT APPLIES TO: Beausoleil et al. v. Takeda Pharmaceuticals North America Inc. et. al.; Case No. 6:13-cv-3184
JUDGE DOHERTY REPORT AND RECOMMENDATIONS ON UNOPPOSED MOTION FOR SETTLEMENT AS TO CLAIMS OF DECEDENT , ROLLAND O. BEAUSOLEIL
This Court, having reviewed Plaintiffs' Unopposed Motion to Approve Settlement as to Claims of Susan Randolph, as Executrix of the Estate of Rolland O. Beausoleil and Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A., Inc. (collectively "Takeda"), the parties having received due notice of and having had the opportunity to be heard, and this Court having considered all submissions made, I recommend to the Court that the Motion be
GRANTED and
The settlement by and between Plaintiff, Susan Randolph, as Executrix individually and as legal heir to the Estate of Rolland O. Beausoleil, deceased, and Takeda, as notice to the Court on Date of Notice be
APPROVED.
The Court has jurisdiction of this matter by virtue of the Plaintiff participating in the Actos MDL Master Settlement Agreement.
ANY PARTY OBJECTING TO THIS RECOMMENDATION SHALL SUBMIT OBJECTIONS, IN WRITING, DIRECTLY TO JUDGE DOHERTY'S CHAMBERS - AND SHALL NOT FILE THE OBJECTION INTO THE RECORD - NO LATER THAN TEN (10) DAYS AFTER ENTRY OF THIS RECOMMENDATION.
If there is no objection within ten (10) days of the entry of this Recommendation, the Recommendation will become an Order.
This is DONE AND SIGNED in Lafayette, Louisiana, this 14th of October, 2016.
/s/_________
HONORABLE PATRICK J. HANNA
UNITED STATES MAGISTRATE JUDGE